Alexander Maxwell
Value, growth, long-term horizon, biotech

Novavax: A Vaccine Company With Large Long-Term Potential

Novavax (NASDAQ:NVAX) is a small-cap vaccine company, yet it has a very large long-term potential. The company has a great pipeline that is full of depth, and this pipeline should be able to create substantial value for shareholders as it progresses. Furthermore, the recent attempt to merge with Isconova AB should only help to add more depth to the pipeline. Novavax has some very interesting vaccines.


Novavax recently announced a merger with Isconova, in which Novavax will acquire all of the outstanding shares of Isconova. This merger should help to drive long-term growth, given the fact that the companies pipelines seem to compliment one another's quite nicely. The offer values Isconava at $29.6 million. Isconova's board...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details